Home
KYinno

KYinno Market Share Analysis for May 2026

Kyinno's customized cell line construction offers specific mutations, resistance profiles & reporter systems for targeted drug development.

Industry: N/A

Domainkyinno.com

Year Founded2017

Employees51 - 200

Annual Revenue$2M - $5M

KYinno

KYinno (including company regionals)

kyinno.com

See more website traffic and engagement information

KYinno Revenue up to May 2026 is 2M - 5M

revenue generated by KYinno top domains

KYinno top domains revenue over 3 years

Revenue for KYinno top domains

kyinno.com2M - 5M

See more with Sales Intelligence

Total visits to KYinno's top domains

Understand KYinno market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kyinno.com9.5K

See more with Sales Intelligence

Avg. visit duration in KYinno's top domains

Analyze KYinno engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kyinno.com00:00:12

See more with Sales Intelligence

Avg. pageviews on KYinno's top domains

See how KYinno keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kyinno.com1.40

See more with Sales Intelligence

KYinno top competitors by domain

Top similar sites in May 2026, ranked by their affinity

reactionbiology.comCompany NameReaction BiologyEmployees51 - 200HQUnited States, Pennsylvania, MalvernAnnual revenue$10M - $15MTotal visits12.4KScience and Education > Biology

Top technologies used by KYinno

These are the website technologies, by industry, used by KYinno top domains

Payment & Currencies (8)

Cart Functionality

Widget (6)

Twemoji

Advertising (2)

Awin

Content Management System (2)

WordPress

More Technologies

9

See all

News & Signals from KYinno

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKyinno Biotechnology Co. is developing series of high-quality KLK2 / KLK3 cell lines.Based on these targets, the cell biology division of Kyinno Biotechnology has developed a series of high-quality KLK2 / KLK3 cell lines, providing precise and efficient experimental model systems for scientific research and drug screening.

NewsKyinno Biotechnology Co. launches TOP1-R364H-KI gene-edited cell line.To address this challenge, Kyinno Biotechnology has successfully developed the TOP1-R364H-KI gene-edited cell line.

NewsKyinno Biotechnology Co. received financing of $35M in Series B on Dec 15th '25.Artery Network learned at the first opportunity that on December 15, Kyinno Biotechnology, a biotechnology company dedicated to the R&D of next-generation bispecific and multispecific antibody therapeutics, announced the successful completion of its Series B financing, raising nearly USD 35 million.